BACKGROUND & AIMS: Colorectal cancers associated with the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome usually present in younger patients, show loss of mismatch repair (MMR) gene expression, and exhibit microsatellite instability (MSI). About 12% of sporadic colorectal cancers also show MMR loss and MSI. The aims of this study were to evaluate MMR loss and MSI in relation to patient age, sex, tumor stage, and site in the large bowel. METHODS: Tissue microarrays were created from 1020 stage II and III colorectal cancer cases and immunohistochemical staining performed to detect expression of the 2 major MMR proteins, hMLH1 and hMSH2. MSI was determined using the BAT-26 mononucleotide repeat. RESULTS: Ten percent of tumors showed loss of hMLH1 expression and 1.2% showed loss of hMSH2 expression. hMLH1 loss was more frequent in women (P < .001), older patients (P = .004), earlier stage tumors (P = .0001), and proximal colon tumors ( P < .0001). In contrast, tumors showing hMSH2 loss were more frequent in younger (P < .001), male (P = .05) patients and were distributed evenly between the proximal colon and distal colon/rectum. Eleven percent of tumors were MSI+ and these showed similar age, sex, stage, and site characteristics as tumors with hMLH1 loss. Discordance between MMR loss and MSI+ was found in 24 of 983 (2.4%) tumors. Of the 231 patients aged <60 years at diagnosis, 12 (5.2%) showed loss of hMLH1 and 8 (3.5%) showed loss of hMSH2. CONCLUSIONS: Routine immunohistochemical screening for MMR loss in younger colorectal cancer patients may provide a useful, first-step screening tool for the population-based detection of HNPCC.
BACKGROUND & AIMS:Colorectal cancers associated with the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome usually present in younger patients, show loss of mismatch repair (MMR) gene expression, and exhibit microsatellite instability (MSI). About 12% of sporadic colorectal cancers also show MMR loss and MSI. The aims of this study were to evaluate MMR loss and MSI in relation to patient age, sex, tumor stage, and site in the large bowel. METHODS: Tissue microarrays were created from 1020 stage II and III colorectal cancer cases and immunohistochemical staining performed to detect expression of the 2 major MMR proteins, hMLH1 and hMSH2. MSI was determined using the BAT-26 mononucleotide repeat. RESULTS: Ten percent of tumors showed loss of hMLH1 expression and 1.2% showed loss of hMSH2 expression. hMLH1 loss was more frequent in women (P < .001), older patients (P = .004), earlier stage tumors (P = .0001), and proximal colon tumors ( P < .0001). In contrast, tumors showing hMSH2 loss were more frequent in younger (P < .001), male (P = .05) patients and were distributed evenly between the proximal colon and distal colon/rectum. Eleven percent of tumors were MSI+ and these showed similar age, sex, stage, and site characteristics as tumors with hMLH1 loss. Discordance between MMR loss and MSI+ was found in 24 of 983 (2.4%) tumors. Of the 231 patients aged <60 years at diagnosis, 12 (5.2%) showed loss of hMLH1 and 8 (3.5%) showed loss of hMSH2. CONCLUSIONS: Routine immunohistochemical screening for MMR loss in younger colorectal cancerpatients may provide a useful, first-step screening tool for the population-based detection of HNPCC.
Authors: R Soong; N Shah; M Salto-Tellez; B C Tai; R A Soo; H C Han; S S Ng; W L Tan; N Zeps; D Joseph; R B Diasio; B Iacopetta Journal: Ann Oncol Date: 2008-02-01 Impact factor: 32.976
Authors: Mark A Jenkins; Shinichi Hayashi; Anne-Marie O'Shea; Lawrence J Burgart; Tom C Smyrk; David Shimizu; Paul M Waring; Andrew R Ruszkiewicz; Aaron F Pollett; Mark Redston; Melissa A Barker; John A Baron; Graham R Casey; James G Dowty; Graham G Giles; Paul Limburg; Polly Newcomb; Joanne P Young; Michael D Walsh; Stephen N Thibodeau; Noralane M Lindor; Loïc Lemarchand; Steven Gallinger; Robert W Haile; John D Potter; John L Hopper; Jeremy R Jass Journal: Gastroenterology Date: 2007-04-25 Impact factor: 22.682
Authors: Diego Arango; Sheren Al-Obaidi; David S Williams; Higinio Dopeso; Rocco Mazzolini; Georgia Corner; Do-Sun Byun; Azadeh A Carr; Carmel Murone; Lars Tögel; Nikolajs Zeps; Lauri A Aaltonen; Barry Iacopetta; John M Mariadason Journal: Am J Pathol Date: 2012-02-18 Impact factor: 4.307
Authors: P A Candy; M R Phillips; A D Redfern; S M Colley; J A Davidson; L M Stuart; B A Wood; N Zeps; P J Leedman Journal: Br J Cancer Date: 2013-07-30 Impact factor: 7.640
Authors: Angela Chew; Paul Salama; Anneli Robbshaw; Borut Klopcic; Nikolajs Zeps; Cameron Platell; Ian C Lawrance Journal: PLoS One Date: 2011-07-26 Impact factor: 3.240
Authors: Tim J Miller; Melanie J McCoy; Tracey F Lee-Pullen; Chidozie C Anyaegbu; Christine Hemmings; Max K Bulsara; Cameron F Platell Journal: Cancers (Basel) Date: 2020-04-29 Impact factor: 6.639
Authors: R Soong; N Shah; B K Peh; P Y Chong; S S Ng; N Zeps; D Joseph; M Salto-Tellez; B Iacopetta; Y Ito Journal: Br J Cancer Date: 2009-02-17 Impact factor: 7.640